Physician profile
Bradley Harrison
NPI 1821520453
$5,695.05
in general payments reported to CMS, 2019-2025
38 companies · $3,103 in 2025
The $3,103 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.18 · 2020: $249 · 2021: $99.95 · 2022: $345 · 2023: $123 · 2024: $1,760 · 2025: $3,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,900 · Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,900.00 |
| Food and Beverage | $2,086.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,407.56 | 2024-2025 | Imfinzi, Calquence, Lynparza |
| Daiichi Sankyo INC. | $677.18 | 2024-2025 | Vanflyta, Injectafer |
| Incyte Corporation | $244.99 | 2020-2025 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $220.86 | 2022-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $206.29 | 2024-2025 | |
| Gt Medical Technologies, INC | $187.54 | 2025 | Gammatile |
| Eisai INC. | $181.68 | 2020-2025 | |
| Abbvie INC. | $143.77 | 2023-2025 | |
| Kite Pharma, INC. | $110.76 | 2025 | Yescarta |
| Seagen INC. | $99.99 | 2022 | |
| Merck Sharp & Dohme LLC | $90.64 | 2024-2025 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $87.81 | 2025 | Opdualag, Opdivo |
| Astellas Pharma US INC | $85.53 | 2025 | Vyloy, Padcev |
| Helsinn Therapeutics (U.S.), INC. | $76.11 | 2022 | |
| Exelixis INC. | $72.73 | 2024-2025 | Cabometyx |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $70.78 | 2025 | Rybrevant, Darzalex, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $66.72 | 2025 | Alunbrig, Fruzaqla |
| Glaxosmithkline, LLC. | $60.42 | 2025 | Blenrep, Zejula, Jemperli |
| Pfizer INC. | $58.10 | 2025 | |
| Gilead Sciences, INC. | $51.53 | 2025 | Trodelvy |
| Foundation Medicine, INC. | $48.01 | 2022 | |
| Aveo Pharmaceuticals, INC. | $44.89 | 2025 | |
| Pharmaessentia USA Corporation | $43.33 | 2025 | Besremi |
| Celgene Corporation | $39.49 | 2024-2025 | Reblozyl, Pomalyst |
| Legend Biotech USA INC. | $37.08 | 2025 | Carvykti |
| Genentech USA, INC. | $31.85 | 2025 | Phesgo, Itovebi |
| Beone Medicines USA, INC. | $28.22 | 2025 | Tevimbra |
| Deciphera Pharmaceuticals INC. | $27.36 | 2025 | Qinlock |
| Alexion Pharmaceuticals, INC. | $22.68 | 2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $22.04 | 2025 | Monoferric |
| Genmab U.S., INC. | $21.98 | 2025 | Epkinly |
| Fennec Pharmaceuticals, INC. | $21.54 | 2025 | Fyarro |
| Array Biopharma INC | $20.48 | 2025 | Talzenna, Mektovi, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $18.83 | 2025 | |
| Emd Serono, INC. | $17.90 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.57 | 2024 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $15.63 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.